News Focus
News Focus
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 562

Tuesday, 02/26/2019 4:30:00 PM

Tuesday, February 26, 2019 4:30:00 PM

Post# of 9090
RVNC 4Q18 results—2019 cash-burn guidance=$148-158M*:

https://investors.revance.com/news-releases/news-release-details/revance-releases-fourth-quarter-and-full-year-2018-results

The FDA agreed that the 351(k) pathway is appropriate for the Botox-biosimilar program partnered with MYL.

Guidance for the RT002 BLA submission remains “1H19”.

*RVNC’s 1/31/19 cash was $296M, according to the CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”